Hematologic Oncology | Specialty

The OncLive Hematology Oncology condition center page is a comprehensive resource for clinical news and expert insights on various hematologic malignancies, including leukemias, lymphomas, myeloproliferative neoplasms, multiple myeloma, and much more. This section features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in hematologic cancers.

OncLive’s December Roundup of Key FDA Approvals in Oncology

December 30th 2024

Here is your snapshot of all therapeutic options greenlit by the FDA in December 2024 spanning tumor types.

Paying It Forward: The Importance of Mentorship in a Medical Career

December 29th 2024

Beyond a lengthy list of accomplishments across the leukemia spectrum of treatment, Garcia-Manero holds the importance of mentorship as incredibly dear to his heart and a way to pass the torch forward in cancer care.

Tailor-Made for a Lifelong Pursuit of Precision in Cancer Care

December 23rd 2024

With a focus on closing gaps in cancer care for underserved populations, Joseph A. Sparano, MD, FACP, always strives to put patients first—a quality that has become a hallmark of his research and career in oncology.

Venetoclax Plus PegC May Overcome Resistance to Prior BCL-2 Inhibitors in R/R AML

December 20th 2024

The addition of pegcrisantaspase to venetoclax may overcome resistance to prior BCL-2 inhibitor–based regimens for patients with relapsed/refractory AML.

Uproleselan Plus Chemo Fails to Improve OS in R/R AML in China

December 20th 2024

Uproleselan plus chemotherapy did not improved overall survival in relapsed/refractory acute myeloid leukemia.

Olverembatinib Demonstrates Efficacy and Safety in Heavily Pretreated CP-CML

December 19th 2024

Olverembatinib demonstrated preliminary efficacy and was well tolerated in patients with heavily pretreated chronic-phase myeloid leukemia.

NX-5948 Receives FDA Fast Track Designation for R/R Waldenström Macroglobulinemia

December 19th 2024

The FDA granted fast track designation to NX-5948 for Waldenstrom macroglobulinemia that is relapsed/refractory to at least 2 lines of therapy.

FDA Approves Remestemcel-L for Pediatric Steroid-Refractory Acute Graft-vs-Host Disease

December 18th 2024

The FDA has approved remestemcel-L-rknd for pediatric steroid-refractory acute graft-vs-host disease.

Factors That Influence Treatment Decisions in Later-Line CML

December 18th 2024

Javier Pinilla, MD, PhD, and Talha Badar, MBBS, MD, discuss factors that influence later-line treatment choices in chronic myeloid leukemia.

Implications of the FDA Approval of Asciminib for Newly Diagnosed, Ph+ CP-CML

December 18th 2024

Javier Pinilla, MD, PhD, and Talha Badar, MBBS, MD, on the implications of the FDA approval of asciminib in newly diagnosed CP-CML.

Orca-Q Leads to Low Rates of GVHD, Non-Relapse Mortality in High-Risk Hematologic Malignancies

December 16th 2024

Orca-Q led to low rates of graft-vs-host disease and non-relapse mortality in high-risk hematologic malignancies.

100-mg Bezuclastinib Improves Symptoms, Biomarkers in Non-Advanced Systemic Mastocytosis

December 13th 2024

Treatment with a 100-mg dose of bezuclastinib had a favorable safety and tolerability profile in patients with non-advanced systemic mastocytosis.

Iopofosine I 131 Is Efficacious, Tolerable in Heavily Pretreated R/R Waldenström Macroglobulinemia

December 12th 2024

Iopofosine I 131 demonstrated durable efficacy and tolerability in heavily pretreated relapsed/refractory Waldenström macroglobulinemia.

Risk Management Measures Improved Safety, Prevention, and Management of Ponatinib-Associated AEs in CML and AML

December 11th 2024

Select safety measures have improved the prevention and management of risks associated with ponatinib in ALL and CML over 10 years.

IO-202 Plus Azacitidine Elicits Responses in HMA-Naive Chronic Myelomonocytic Leukemia

December 11th 2024

IO-202 plus azacitidine elicited an ORR of 66.7% in patients with HMA-naive chronic myelomonocytic leukemia.

NFKB1 Haplotype Decreases Inflammation, Increases Response to Ropeginterferon Alfa-2b in PV and ET

December 11th 2024

NFKB1 rs230511 reduces inflammation and amplifies responses to ropeginterferon alfa-2b in polycythemia vera and essential thrombocythemia.

Tafasitamab Plus Lenalidomide/Rituximab Improves PFS in Relapsed/Refractory Follicular Lymphoma

December 10th 2024

Tafasitamab plus lenalidomide and rituximab improved median PFS vs lenalidomide and rituximab in patients with relapsed/refractory follicular lymphoma.

Dr Wang on Ziftomenib Plus Intensive Induction in Newly Diagnosed, NPM1+ or KMT2A+ AML

December 10th 2024

Eunice S. Wang, MD, on ziftomenib plus intensive induction in newly diagnosed, NPM1-mutated or KMT2A-rearranged acute myeloid leukemia.

BGB-16673 Demonstrates Initial Antitumor Activity, Tolerability in Select Relapsed/Refractory B-Cell Malignancies

December 10th 2024

BGB-16673 monotherapy showed early activity and a tolerable safety profile in relapsed/refractory Waldenström macroglobulinemia, CLL, and SLL.

Breaking the News in Myeloma, GVHD, and NHL, With Drs Rajkumar, Farhadfar, and Smith

December 10th 2024

S. Vincent Rajkumar, MD, of Mayo Clinic; Nosha Farhadfar, MD, of Methodist Physician Practices; and Sonali Smith, MD, of University of Chicago Medicine, sit down with Chandler Park, MD, FACP, to discuss the latest in multiple myeloma, graft-vs-host disease, and non-Hodgkin lymphoma, respectively, from the 2024 ASH Annual Meeting.